APA

Pietanza M. C., Lynch T. J., Lara P. N., Cho J., Yanagihara R. H., Vrindavanam N., Chowhan N. M., Gadgeel S. M., Pennell N. A., Funke R., Mitchell B., Wakelee H. A. & Miller V. A. (20120504). XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chicago

Pietanza M Catherine, Lynch Thomas James, Lara Primo N, Cho John, Yanagihara Ronald H, Vrindavanam Nandagopal, Chowhan Naveed Mahfooz, Gadgeel Shirish M, Pennell Nathan A, Funke Roel, Mitchell Ben, Wakelee Heather A and Miller Vincent A. 20120504. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Harvard

Pietanza M. C., Lynch T. J., Lara P. N., Cho J., Yanagihara R. H., Vrindavanam N., Chowhan N. M., Gadgeel S. M., Pennell N. A., Funke R., Mitchell B., Wakelee H. A. and Miller V. A. (20120504). XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MLA

Pietanza M Catherine, Lynch Thomas James, Lara Primo N, Cho John, Yanagihara Ronald H, Vrindavanam Nandagopal, Chowhan Naveed Mahfooz, Gadgeel Shirish M, Pennell Nathan A, Funke Roel, Mitchell Ben, Wakelee Heather A and Miller Vincent A. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 20120504.